Literature DB >> 25273169

Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.

Jianxin Shi1, Hongcheng Liu, Feng Yao, Chenxi Zhong, Heng Zhao.   

Abstract

Mediator complex subunit MED23 has been reported to facilitate the transformation induced by oncogenic Ras in non-small-cell lung carcinoma (NSCLC). However, the expression pattern and biological functions of MED23 in the progression of NSCLC are not fully understood. In this study, it was found that the expression of MED23 was significantly upregulated in NSCLC samples compared to their adjacent normal tissues. Moreover, in the biological function studies, overexpression of MED23 was further validated to promote the growth, migration, and metastasis of NSCLC cells, while knockdown of the expression of MED23 inhibited the growth, migration, and metastasis of NSCLC cells in vitro and in vivo. Mechanistically, MED23 was found to interact with beta-catenin and activate beta-catenin/TCF signaling. Our study demonstrated that MED23 played an oncogenic role in the progression of NSCLC and that MED23 might be a promising target for the treatment of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25273169     DOI: 10.1007/s13277-014-2499-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  The multitalented Mediator complex.

Authors:  Jonas O P Carlsten; Xuefeng Zhu; Claes M Gustafsson
Journal:  Trends Biochem Sci       Date:  2013-09-25       Impact factor: 13.807

2.  Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.

Authors:  Ji-Youn Han; Sun Hye Kim; Yeon-Su Lee; Seung-Youn Lee; Jung-Ah Hwang; Jin Young Kim; Sung Jin Yoon; Geon Kook Lee
Journal:  Lung Cancer       Date:  2014-04-29       Impact factor: 5.705

3.  Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

Authors:  Myung-Ju Ahn; Sang-We Kim; Byoung-Chul Cho; Jin Seok Ahn; Dae Ho Lee; Jong-Mu Sun; Dan Massey; Miyoung Kim; Yang Shi; Keunchil Park
Journal:  Oncologist       Date:  2014-05-27

4.  The Mediator Complex and Lipid Metabolism.

Authors:  Yi Zhang; Xiaoping Zhao; Fajun Yang
Journal:  J Biochem Pharmacol Res       Date:  2013-03

5.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

6.  Mediator coordinates PIC assembly with recruitment of CHD1.

Authors:  Justin J Lin; Lynn W Lehmann; Giancarlo Bonora; Rupa Sridharan; Ajay A Vashisht; Nancy Tran; Kathrin Plath; James A Wohlschlegel; Michael Carey
Journal:  Genes Dev       Date:  2011-10-06       Impact factor: 11.361

7.  Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit.

Authors:  Jennitte L Stevens; Greg T Cantin; Gang Wang; Andrej Shevchenko; Anna Shevchenko; Arnold J Berk
Journal:  Science       Date:  2002-04-04       Impact factor: 47.728

8.  [The functional interaction of an RNA polymerase II Rpb11 subunit with the Med18 subunit (Srb5) of the Saccharomyces cerevisiae mediator complex].

Authors:  G M Proshkina; G V Shpakovskiĭ
Journal:  Bioorg Khim       Date:  2009 Jul-Aug

9.  CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.

Authors:  Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

10.  Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Authors:  O Alejandro Balbin; John R Prensner; Anirban Sahu; Anastasia Yocum; Sunita Shankar; Rohit Malik; Damian Fermin; Saravana M Dhanasekaran; Benjamin Chandler; Dafydd Thomas; David G Beer; Xuhong Cao; Alexey I Nesvizhskii; Arul M Chinnaiyan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  3 in total

1.  The Mediator subunit MED23 couples H2B mono-ubiquitination to transcriptional control and cell fate determination.

Authors:  Xiao Yao; Zhanyun Tang; Xing Fu; Jingwen Yin; Yan Liang; Chonghui Li; Huayun Li; Qing Tian; Robert G Roeder; Gang Wang
Journal:  EMBO J       Date:  2015-09-01       Impact factor: 11.598

2.  Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets.

Authors:  Ying Zhang; Chao You; Yuchen Pei; Fan Yang; Daqiang Li; Yi-Zhou Jiang; Zhimin Shao
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

3.  Novel mutation in the MED23 gene for intellectual disability: A case report and literature review.

Authors:  Feyzollah Hashemi-Gorji; Majid Fardaei; Seyed Mohammad Bagher Tabei; Mohammad Miryounesi
Journal:  Clin Case Rep       Date:  2019-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.